skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 2,450  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials
Material Type:
Article
Add to My Research

The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials

European heart journal, 2021-03, Vol.42 (9), p.896-903 [Peer Reviewed Journal]

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. ;Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. 2021 ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehaa1034 ;PMID: 33417682

Full text available

2
Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress
Material Type:
Article
Add to My Research

Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress

Journal of advanced research, 2021-12, Vol.34, p.43-63 [Peer Reviewed Journal]

2021 ;2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University. ;2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University. 2021 ;ISSN: 2090-1232 ;EISSN: 2090-1224 ;DOI: 10.1016/j.jare.2021.06.023 ;PMID: 35024180

Full text available

3
Prevalence of statin intolerance: a meta-analysis
Material Type:
Article
Add to My Research

Prevalence of statin intolerance: a meta-analysis

European heart journal, 2022-09, Vol.43 (34), p.3213-3223 [Peer Reviewed Journal]

The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. ;The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. 2022 ;ISSN: 0195-668X ;ISSN: 1522-9645 ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehac015 ;PMID: 35169843

Full text available

4
Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis
Material Type:
Article
Add to My Research

Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis

Cell, 2015-12, Vol.163 (7), p.1585-1595 [Peer Reviewed Journal]

2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2015.11.055 ;PMID: 26687352

Full text available

5
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations
Material Type:
Article
Add to My Research

Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations

Circulation (New York, N.Y.), 2016-06, Vol.133 (24), p.2459-2502 [Peer Reviewed Journal]

2016 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2016 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.116.022194 ;PMID: 27297342

Full text available

6
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Material Type:
Article
Add to My Research

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association

Arteriosclerosis, thrombosis, and vascular biology, 2022-01, Vol.42 (1), p.e48-e60 [Peer Reviewed Journal]

ISSN: 1079-5642 ;EISSN: 1524-4636 ;DOI: 10.1161/atv.0000000000000147 ;PMID: 34647487

Full text available

7
Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products
Material Type:
Article
Add to My Research

Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products

Pharmacological reviews, 2019-10, Vol.71 (4), p.596-670 [Peer Reviewed Journal]

Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. ;ISSN: 0031-6997 ;EISSN: 1521-0081 ;DOI: 10.1124/pr.118.017178 ;PMID: 31554644

Full text available

8
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Material Type:
Article
Add to My Research

Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis

European heart journal, 2020-08, Vol.41 (31), p.2983-2996 [Peer Reviewed Journal]

The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. 2020 ;The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehz919 ;PMID: 31898722

Full text available

9
Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction
Material Type:
Article
Add to My Research

Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction

European heart journal, 2020-07, Vol.41 (28), p.2681-2695 [Peer Reviewed Journal]

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. 2019 ;Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehz112 ;PMID: 30903157

Full text available

10
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
Material Type:
Article
Add to My Research

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Circulation (New York, N.Y.), 2022-10, Vol.146 (15), p.1109-1119 [Peer Reviewed Journal]

ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.122.061620 ;PMID: 36031810

Full text available

11
Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque
Material Type:
Article
Add to My Research

Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque

Circulation (New York, N.Y.), 2020-12, Vol.142 (24), p.2299-2311 [Peer Reviewed Journal]

2020 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.120.049981 ;PMID: 33003973

Full text available

12
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Material Type:
Article
Add to My Research

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

The New England journal of medicine, 2017-09, Vol.377 (12), p.1119-1131 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1707914 ;PMID: 28845751

Full text available

13
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Material Type:
Article
Add to My Research

Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis

Nature reviews cardiology, 2022-04, Vol.19 (4), p.228-249 [Peer Reviewed Journal]

2021. Springer Nature Limited. ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1759-5002 ;ISSN: 1759-5010 ;EISSN: 1759-5010 ;DOI: 10.1038/s41569-021-00629-x ;PMID: 34759324

Full text available

14
Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines
Material Type:
Article
Add to My Research

Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines

Nature communications, 2020-05, Vol.11 (1), p.2622-14, Article 2622 [Peer Reviewed Journal]

The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-020-16439-7 ;PMID: 32457361

Full text available

15
Response by O'Donoghue et al to Letter Regarding Article, "Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease"
Material Type:
Article
Add to My Research

Response by O'Donoghue et al to Letter Regarding Article, "Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease"

Circulation (New York, N.Y.), 2023-04, Vol.147 (16), p.1258-1259 [Peer Reviewed Journal]

ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.123.064048 ;PMID: 37068132

Full text available

16
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial
Material Type:
Article
Add to My Research

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

The Lancet (British edition), 2022-07, Vol.400 (10349), p.380-390 [Peer Reviewed Journal]

Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00916-3 ;PMID: 35863366

Full text available

17
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Material Type:
Article
Add to My Research

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

The New England journal of medicine, 2017-10, Vol.377 (14), p.1319-1330 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1709118 ;PMID: 28844192

Full text available

18
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Material Type:
Article
Add to My Research

Inflammatory processes in cardiovascular disease: a route to targeted therapies

Nature reviews cardiology, 2017-03, Vol.14 (3), p.133-144 [Peer Reviewed Journal]

COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Mar 2017 ;ISSN: 1759-5002 ;EISSN: 1759-5010 ;DOI: 10.1038/nrcardio.2016.185 ;PMID: 27905474

Full text available

19
Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond
Material Type:
Article
Add to My Research

Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond

Journal of the American College of Cardiology, 2017-10, Vol.70 (18), p.2278-2289 [Peer Reviewed Journal]

Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Oct 31, 2017 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2017.09.028 ;PMID: 29073957

Full text available

20
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents
Material Type:
Article
Add to My Research

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents

Journal of the American College of Cardiology, 2016-07, Vol.68 (1), p.92-125 [Peer Reviewed Journal]

Copyright Elsevier Limited Jul 5, 2016 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.03.519 ;PMID: 27046161

Full text available

Results 1 - 20 of 2,450  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (2,324)

Refine My Results

Creation Date 

From To
  1. Before 2005  (8)
  2. 2005 To 2009  (548)
  3. 2010 To 2014  (627)
  4. 2015 To 2020  (785)
  5. After 2020  (484)
  6. More options open sub menu

Resource Type 

  1. Articles  (2,447)
  2. Web Resources  (1)
  3. magazinearticle  (1)
  4. Books  (1)
  5. More options open sub menu

Language 

  1. English  (2,408)
  2. Japanese  (506)
  3. French  (11)
  4. Portuguese  (11)
  5. Swedish  (8)
  6. Russian  (7)
  7. Spanish  (7)
  8. Chinese  (6)
  9. Polish  (4)
  10. German  (4)
  11. Italian  (2)
  12. Turkish  (2)
  13. Ukrainian  (1)
  14. More options open sub menu

Searching Remote Databases, Please Wait